Request appointment
417 East 68th StreetNew York, NY 10065
Overview of Dr. Iacobuzio-Donahue
Dr. Christine Iacobuzio-Donahue is a pathologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. She received her medical degree from Boston University School of Medicine and has been in practice 28 years. She is one of 173 doctors at Memorial Sloan Kettering Cancer Center who specialize in Pathology. She has more than 100 publications and over 500 citings.
Education & Training
Boston University School of MedicineClass of 1998
Certifications & Licensure
NY State Medical License 2014 - 2027
MD State Medical License 2002 - 2014
American Board of Pathology Anatomic Pathology
Publications & Presentations
PubMed
- SPINK1-COL18A1 crosstalk shapes epigenome and drives cancer stemness in pancreatic ductal adenocarcinoma.Haoyu Tang, Bethsebie Sailo, Xingbo Shang, Md Shahadat Hossan, Jeremy Kratz
Cell Reports. 2026-08-18 - Pancreatic Cancer: Translating Tumor Biology into Actionability.Fiyinfolu O Balogun, Mara H Sherman, Wungki Park, Kevin C Soares, Marsha Reyngold
Cancer Discovery. 2026-07-01 - Mutant KRAS-driven selective mRNA translation reveals mechanisms and therapeutic vulnerabilities in cancer.Ankita Shrivastava, Eric Nels Pederson, Trang Uyen Nguyen, Jacky Chuen, Prathibha Mohan
Cell Reports. 2026-06-23
Press Mentions
A Single Genetic Mutation Has Made People More Susceptible to CancerMay 8th, 2022- A Single Genetic Mutation Made Humans More Susceptible to CancerMay 3rd, 2022
- Pancreatic Cancer: Keynote Highlights Trainees, Rising Stars, and Distinguished ProfessorsNovember 4th, 2023
Grant Support
- Determining the mechanism of pks+ E.coli-associated carcinogenesis in early onset colorectal cancer.SLOAN-KETTERING INST CAN RESEARCH2022–2027
- Improving Outcome in Patients with Advanced Intrahepatic Cholangiocarcinoma: A Randomized Phase II Study of Gemcitabine and Oxaliplatin With or Without Regional Floxuridine (FUDR)SLOAN-KETTERING INST CAN RESEARCH2020–2025
- Improving Outcome in Patients with Advanced Intrahepatic Cholangiocarcinoma: A Randomized Phase II Study of Gemcitabine and Oxaliplatin With or Without Regional Floxuridine (FUDR)SLOAN-KETTERING INST CAN RESEARCH2020–2025
- Interrogating the Evolutionary Dynamics of Cancer for Clinical Benefit and ActionabilitySLOAN-KETTERING INST CAN RESEARCH2018–2025
- Interrogating the Evolutionary Dynamics of Cancer for Clinical Benefit and ActionabilitySLOAN-KETTERING INST CAN RESEARCH2018–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
